Linked Life Data

2419679

Source:http://linkedlifedata.com/resource/pubmed/id/2419679

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1986-3-31
pubmed:abstractText
Pirmenol, a new class I antiarrhythmic drug, was given for the treatment of frequent premature ventricular complexes (PVCs) over a 6-month period. Ten patients who had their arrhythmia effectively suppressed by pirmenol in a dose-ranging study were treated with the lowest effective doses in an open investigation. The mean daily doses were 315 mg at the beginning and 340 mg at the end of 6 months. The mean reduction in the frequency of PVC/h remained between 85.5 and 88.6% during 24-h ambulatory electrocardiogram recordings at 1, 3, 5, and 6 months of therapy. With adjustment of the dosage, the predetermined efficacy criteria were fulfilled by eight to 10 patients at each of the four assessments. The PVC/h or repetitive PVC/h frequencies of the patient group did not decline spontaneously within 6 months of treatment, as shown in a placebo control phase. No aggravation of arrhythmias was observed. Side effects in two patients did not prevent prolonged use.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0160-2446
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
156-60
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:articleTitle
Pirmenol in the long-term treatment of chronic ventricular arrhythmias: a placebo-controlled study.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't